Nikunj Patel

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · The Lancet Oncology · 2024 · 132 citations

Medicine, Oncology, Pharmacology +11

The impact of economic growth, trade openness and manufacturing on CO2 emissions in India: an autoregressive distributive lag (ARDL) bounds test approach

Yaswanth Karedla, Rohit Mishra, Nikunj Patel · Journal of Economics Finance and Administrative Science · 2021 · 72 citations · Full text

Social Sciences, Economics, Development Economics +12

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen et al. · Lung Cancer · 2020 · 55 citations · Full text

Medicine, Oncology, Pharmacology +13

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Luis Paz‐Ares, Jonathan W. Goldman, Marina Chiara Garassino et al. · Annals of Oncology · 2019 · 52 citations · Full text

Medicine, Oncology, Pharmacology +10

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Bruno Sangro, Peter R. Galle, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2024 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +15